Gelderblom, H., Forde, P. M., Naing, A., Taylor, M., Mataraza, J., Butler, M. O., . . . Cameron, S. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors. BMJ Publishing Group.
Chicago Style (17th ed.) CitationGelderblom, Hans, et al. A First-in-human Phase 1 Dose Escalation Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, in Patients with Advanced Solid Tumors. BMJ Publishing Group.
MLA (9th ed.) CitationGelderblom, Hans, et al. A First-in-human Phase 1 Dose Escalation Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, in Patients with Advanced Solid Tumors. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.